IDH2 and astrocytoma (excluding glioblastoma): We notably did not detect significant differences in response to ivosidenib for lower grades (2 vs. 3), age (older vs. younger than 40 years old), histology (astrocytoma vs. oligodendroglioma), or IDH mutation (canonical vs. noncanonical).